Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.
Henry MaBruce C V CampbellMark W ParsonsLeonid ChurilovChristopher R LeviChung HsuTimothy J KleinigTissa WijeratneSami CurtzeHelen M DeweyFerdinand MiteffChon-Haw TsaiJiunn-Tay LeeThanh G PhanNeil MahantMu-Chien SunMartin KrauseJonathan SturmRohan GrimleyChih-Hung ChenChaur-Jong HuAndrew A WongDeborah FieldYu SunP Alan BarberArman SabetJim JannesJiann-Shing JengBenjamin ClissoldRomesh MarkusChing-Huang LinLi-Ming LienChristopher F BladinSøren ChristensenNawaf YassiGagan SharmaAndrew BivardPatricia M DesmondBernard YanPeter J MitchellVincent N ThijsLeeanne CareyAtte MeretojaStephen M DavisGeoffrey A Donnannull nullPublished in: The New England journal of medicine (2019)
Among the patients in this trial who had ischemic stroke and salvageable brain tissue, the use of alteplase between 4.5 and 9.0 hours after stroke onset or at the time the patient awoke with stroke symptoms resulted in a higher percentage of patients with no or minor neurologic deficits than the use of placebo. There were more cases of symptomatic cerebral hemorrhage in the alteplase group than in the placebo group. (Funded by the Australian National Health and Medical Research Council and others; EXTEND ClinicalTrials.gov numbers, NCT00887328 and NCT01580839.).
Keyphrases
- atrial fibrillation
- acute ischemic stroke
- phase iii
- end stage renal disease
- cerebral ischemia
- ejection fraction
- newly diagnosed
- healthcare
- chronic kidney disease
- high resolution
- clinical trial
- prognostic factors
- subarachnoid hemorrhage
- case report
- double blind
- computed tomography
- white matter
- randomized controlled trial
- multiple sclerosis
- phase ii
- magnetic resonance
- photodynamic therapy
- blood brain barrier
- patient reported
- resting state
- patient reported outcomes
- sleep quality